University Clinic of Muenster, Department of Orthopaedics and Tumour Orthopaedics, Albert-Schweitzer-Str. 33, Muenster, Germany.
Bone Joint J. 2013 Oct;95-B(10):1425-31. doi: 10.1302/0301-620X.95B10.31740.
We evaluated the clinical results and complications after extra-articular resection of the distal femur and/or proximal tibia and reconstruction with a tumour endoprosthesis (MUTARS) in 59 patients (mean age 33 years (11 to 74)) with malignant bone or soft-tissue tumours. According to a Kaplan-Meier analysis, limb survival was 76% (95% confidence interval (CI) 64.1 to 88.5) after a mean follow-up of 4.7 years (one month to 17 years). Peri-prosthetic infection was the most common indication for subsequent amputation (eight patients). Survival of the prosthesis without revision was 48% (95% CI 34.8 to 62.0) at two years and 25% (95% CI 11.1 to 39.9) at five years post-operatively. Failure of the prosthesis was due to deep infection in 22 patients (37%), aseptic loosening in ten patients (17%), and peri-prosthetic fracture in six patients (10%). Wear of the bearings made a minor revision necessary in 12 patients (20%). The mean Musculoskeletal Tumor Society score was 23 (10 to 29). An extensor lag > 10° was noted in ten patients (17%). These results suggest that limb salvage after extra-articular resection with a tumour prosthesis can achieve good functional results in most patients, although the rates of complications and subsequent amputation are higher than in patients treated with intra-articular resection.
我们评估了 59 例(平均年龄 33 岁(11 至 74 岁))恶性骨或软组织肿瘤患者采用肿瘤假体(MUTARS)行关节外股骨远端和/或胫骨近端切除和重建的临床结果和并发症。根据 Kaplan-Meier 分析,平均随访 4.7 年后(1 个月至 17 年),肢体存活率为 76%(95%置信区间(CI)64.1 至 88.5)。假体周围感染是随后截肢的最常见原因(8 例)。未翻修的假体存活率在术后 2 年时为 48%(95%CI 34.8 至 62.0),在术后 5 年时为 25%(95%CI 11.1 至 39.9)。假体失败的原因是 22 例(37%)深部感染、10 例(17%)无菌性松动和 6 例(10%)假体周围骨折。12 例(20%)因轴承磨损需要进行小翻修。肌肉骨骼肿瘤学会评分平均为 23 分(10 至 29 分)。10 例患者(17%)存在伸肌滞后> 10°。这些结果表明,采用肿瘤假体行关节外切除后保肢可以使大多数患者获得良好的功能结果,尽管并发症和随后截肢的发生率高于采用关节内切除的患者。